Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical trial with lozenges as local pain treatment for head and neck cancer patients with oral mucostis

Trial Profile

Clinical trial with lozenges as local pain treatment for head and neck cancer patients with oral mucostis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bupivacaine (Primary)
  • Indications Pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Mar 2016 Results published in Moberg Pharma media release.
    • 11 Jan 2016 Primary endpoint has been met (Measurement of the oral pain on a visual analogue scale), according to a Moberg Pharma media release.
    • 11 Jan 2016 Status changed from recruiting to completed, according to a Moberg Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top